Dr. Jon D. Olson, MD
Neurology (Neurology Physician)
10101 Park Rowe Ave, Suite 200
Baton Rouge, LA 70810
Who else practices at this address →
East Baton Rouge Parish includes primary care (46% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Iowa, Rj & L Carver College of Medicine (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 396
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: University of Iowa, Rj & L Carver College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
LA license 13226R
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Our Lady of the Lake Regional Medical Center Baton Rouge, LA
- Baton Rouge General Medical Center Baton Rouge, LA
- Lane Regional Medical Center Zachary, LA
- The Spine Hospital of Louisiana Baton Rouge, LA
Medical groups
- Neuromedical Center (118 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 396
- Services billed
- 1,360
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Injection, gadobutrol, 0.1 ml | 805 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 239 | 193 |
| Established patient office or other outpatient visit, 40-54 minutes | 107 | 88 |
| New patient office or other outpatient visit, 60-74 minutes | 90 | 90 |
| Established patient office or other outpatient visit, 20-29 minutes | 59 | 57 |
| Needle measurement of electrical activity in arm or leg muscles, limited study | 39 | 24 |
| New patient office or other outpatient visit, 45-59 minutes | 35 | 35 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 33 | 20 |
| Measurement of brain wave activity (eeg) outside the brain during surgery | 30 | 30 |
| Nerve conduction, 13 or more studies | 18 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 30 companies reported 194 payments worth $3,716 in total to this clinician.
| AbbVie Inc. | $555 |
|---|---|
| Pfizer Inc. | $332 |
| Neurocrine Biosciences, Inc. | $309 |
| Tg Therapeutics, Inc. | $307 |
| Biogen, Inc. | $233 |
| Amgen Inc. | $202 |
| EMD Serono, Inc. | $196 |
| Argenx US, Inc. | $177 |
| Food and Beverage | $3,692 |
|---|---|
| Education | $24.22 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Springworks Therapeutics, Inc. Jul 29, 2025 | Education GOMEKLI · in-kind | $24.22 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $726,646 in research payments for these studies, mostly to the institutions running them.
- An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis
Novartis Pharmaceuticals Corporation - A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After …
Novartis Pharmaceuticals Corporation - Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141473 - A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Genzyme Corporation · Active, not recruiting · NCT06372145 - Evaluation of Fenebrutinib in RMS patients
Genentech, Inc. - EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma
Novocure GmbH - Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141486 - Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)
Genzyme Corporation · Completed · NCT04410991
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.